Recombinant monoclonal antibody to HLA-DR10. This antibody intended for the prophylaxis and treatment of Breast cancer.
Figure 1 Immunoperoxidase staining of Lym-1 and Lym-2 monoclonal antibodies with an intermediate grade lymphoma.
Lym-1 (× 720).
Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F. M., Parker, J. W., & Taylor, C. R. (1987). Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Research, 47(3), 830-840.
Figure 2 Flow cytometric analysis of Lym-1 staining reactivity with normal peripheral blood lymphocytes.
Lym-1
Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F. M., Parker, J. W., & Taylor, C. R. (1987). Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Research, 47(3), 830-840.
Figure 3 Fluorescent microscopy (400×) of HLA-DR10-expressing Raji lymphoma cells stained with mLym-1.
The Raji cell membrane distribution of the SHALs and mLym-1 were remarkably similar.
West, J., Perkins, J., Hok, S., Balhorn, R., Lightstone, F. C., Cosman, M., ... & DeNardo, G. L. (2006). Direct antilymphoma activity of novel, first-generation" antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer biotherapy & radiopharmaceuticals, 21(6), 645-654.
Figure 4 Growth inhibitory effect on Raji cells.
At 48 hours, chLym-1 (-□-) caused a significant growth inhibitory effect over the range of 0.01-0.13 μM. Wells incubated with 0.13 μM of chLym-1 contained 90%
fewer cells than untreated cells. LeLPLDB (-●-), (Leac- PLD)2PLDB (-○-), and ItPLDB (-■-) caused no growth-inhibitory effect over the same concentration range. Error bars represent the range of duplicate measurements. These data are representative of replicate trials that showed reproducible results.
West, J., Perkins, J., Hok, S., Balhorn, R., Lightstone, F. C., Cosman, M., ... & DeNardo, G. L. (2006). Direct antilymphoma activity of novel, first-generation" antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer biotherapy & radiopharmaceuticals, 21(6), 645-654.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-362CL | Mouse Anti-HLA-DR10 Recombinant Antibody (TAB-362CL) | WB, IHC | Mouse IgG2a |
TAB-096CT-S(P) | Anti-Human HLA-DR10 Recombinant Antibody scFv Fragment (Lym-1) | ELISA, WB | |
TAB-096CT-F(E) | Anti-Human HLA-DR10 Recombinant Antibody Fab Fragment (Lym-1) | ELISA, WB |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0617-WJ | Human Anti-HLA-DR10 Recombinant Antibody (clone ChLym-1) | Inhib | Humanized IgG |
HPAB-1183-FY | Human Anti-HLA-DR10 Recombinant Antibody (clone FY-003) | Inhib | Humanized IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0617-WJ-F(E) | Human Anti-HLA-DR10 Recombinant Antibody (clone ChLym-1); Fab Fragment | Block, FC | Humanized Fab |
HPAB-1183-FY-S(P) | Human Anti-HLA-DR10 Recombinant Antibody (clone FY-003); Fab Fragment | Inhib | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0617-WJ-S(P) | Human Anti-HLA-DR10 Recombinant Antibody (clone ChLym-1); scFv Fragment | Block, FC | Humanized scFv |
HPAB-1183-FY-F(E) | Human Anti-HLA-DR10 Recombinant Antibody (clone FY-003); scFv Fragment | Inhib | Humanized scFv |
There are currently no Customer reviews or questions for TAB-096CT. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.